S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
New CBOE “special perk” helps traders target income every weekend (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
New CBOE “special perk” helps traders target income every weekend (Ad)
Power Play: GE's game-changing technology for EVs and grids
As Dollar Tree Goes, So Goes the Consumer?
New CBOE “special perk” helps traders target income every weekend (Ad)
Is Beyond an overlooked e-commerce winner?
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
New CBOE “special perk” helps traders target income every weekend (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
New CBOE “special perk” helps traders target income every weekend (Ad)
Power Play: GE's game-changing technology for EVs and grids
As Dollar Tree Goes, So Goes the Consumer?
New CBOE “special perk” helps traders target income every weekend (Ad)
Is Beyond an overlooked e-commerce winner?
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
New CBOE “special perk” helps traders target income every weekend (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
New CBOE “special perk” helps traders target income every weekend (Ad)
Power Play: GE's game-changing technology for EVs and grids
As Dollar Tree Goes, So Goes the Consumer?
New CBOE “special perk” helps traders target income every weekend (Ad)
Is Beyond an overlooked e-commerce winner?
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
New CBOE “special perk” helps traders target income every weekend (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
New CBOE “special perk” helps traders target income every weekend (Ad)
Power Play: GE's game-changing technology for EVs and grids
As Dollar Tree Goes, So Goes the Consumer?
New CBOE “special perk” helps traders target income every weekend (Ad)
Is Beyond an overlooked e-commerce winner?
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains

AVROBIO Stock Price, News & Analysis (NASDAQ:AVRO)

$1.32
+0.10 (+8.20%)
(As of 11/30/2023 ET)
Compare
Today's Range
$1.21
$1.32
50-Day Range
$1.22
$1.62
52-Week Range
$0.57
$1.93
Volume
321,108 shs
Average Volume
1.33 million shs
Market Capitalization
$58.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

AVROBIO MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
203.0% Upside
$4.00 Price Target
Short Interest
Healthy
2.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of AVROBIO in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.58 to ($0.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

399th out of 949 stocks

Biological Products, Except Diagnostic Industry

69th out of 163 stocks


AVRO stock logo

About AVROBIO Stock (NASDAQ:AVRO)

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

AVRO Stock Price History

AVRO Stock News Headlines

AVROBIO (NASDAQ:AVRO) Stock Price Down 0.8%
Avrobio Inc AVRO
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
AVROBIO, Inc. (AVRO)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Avrobio (AVRO) Gets a Buy from Barclays
Avrobio to explore strategic options; halts studies
Wedbush Downgrades AvroBio (AVRO)
Gene therapy startup Avrobio explores a sale
AVROBIO to Explore Strategic Alternatives
AVRO - AVROBIO, Inc.
Avrobio (NASDAQ: AVRO)
See More Headlines
Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/28/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVRO
Fax
N/A
Employees
78
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$6.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+203.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-105,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.31 per share

Miscellaneous

Free Float
40,473,000
Market Cap
$58.83 million
Optionable
Not Optionable
Beta
1.39
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Erik John Ostrowski M.B.A. (Age 51)
    President, Interim Chief Executive Officer, CFO & Treasurer
    Comp: $947.29k
  • Ms. Azadeh Golipour Ph.D. (Age 44)
    Chief Technology Officer
    Comp: $728.21k
  • Mr. Jeffrey Medin Ph.D.
    Scientific Founder
  • Mr. Steven N. Avruch J.D. (Age 62)
    Chief Legal Officer & Secretary
    Comp: $506.68k
  • Mr. Scott Gottesman
    Vice President of Human Resource
  • Mr. Andreas Kouri
    Senior Vice President of Global Supply Chain & External Manufacturing
  • Dr. Essra Ridha FFPM (Age 42)
    M.D., Chief Medical Officer
  • Ms. Kirsten Dupuis
    Chief of Staff














AVRO Stock Analysis - Frequently Asked Questions

Should I buy or sell AVROBIO stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AVRO shares.
View AVRO analyst ratings
or view top-rated stocks.

What is AVROBIO's stock price target for 2024?

3 Wall Street analysts have issued 1-year price objectives for AVROBIO's shares. Their AVRO share price targets range from $2.00 to $6.00. On average, they predict the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 203.0% from the stock's current price.
View analysts price targets for AVRO
or view top-rated stocks among Wall Street analysts.

How have AVRO shares performed in 2023?

AVROBIO's stock was trading at $0.7129 at the start of the year. Since then, AVRO stock has increased by 85.2% and is now trading at $1.32.
View the best growth stocks for 2023 here
.

Are investors shorting AVROBIO?

AVROBIO saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 964,900 shares, a drop of 58.2% from the October 31st total of 2,310,000 shares. Based on an average trading volume of 343,700 shares, the short-interest ratio is presently 2.8 days. Currently, 2.5% of the company's shares are sold short.
View AVROBIO's Short Interest
.

When is AVROBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our AVRO earnings forecast
.

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.21.

What other stocks do shareholders of AVROBIO own?
When did AVROBIO IPO?

(AVRO) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.

Who are AVROBIO's major shareholders?

AVROBIO's stock is owned by many different institutional and retail investors. Top institutional investors include BML Capital Management LLC (8.99%), Newtyn Management LLC (4.49%), Acadian Asset Management LLC (3.87%), Terrapin Asset Management LLC (1.25%), Affinity Asset Advisors LLC (1.12%) and Aldebaran Capital LLC (1.06%).
View institutional ownership trends
.

How do I buy shares of AVROBIO?

Shares of AVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AVRO) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -